Study of Dosimetry and Clinical Factors for Assessment of Xerostomia in Head and Neck Squamous Cell Carcinoma Treated by Intensity-modulated Radiotherapy: A Prospective Study

Overview

Journal J Carcinog

Publisher Biomed Central

Date 2021 Nov 3

PMID 34729046

Citations 1

Authors

Vrinda Singla

Vipul Nautiyal

Meenu Gupta

Viney Kumar

Shivani Mehra

Mushtaq Ahmad

Affiliations

Soon will be listed here.

Abstract

Aim: Clinical and dosimetric factors related to toxicity in terms of xerostomia in patients with head and neck squamous cell cancer (HNSCC) treated with intensity-modulated radiotherapy (IMRT).

Materials And Methods: Patients older than 18 years, with the WHO Performance Status Score <2 with primary diagnosis of HNSCC Stage II, III, and IV who had undergone primary or postoperative radiotherapy (RT) treated by IMRT at the center, from November 2015 to November 2016 were included in the study. Patients were assessed by physical examination and questioned to score their quality of life for dryness (HNDR) and stickiness (HNSS) by EORTC-HN-35 (Hindi or English version) at baseline (before treatment), at 3, 6, and 12 months following treatment. The validation of EORTC-HN-35 for HNDR and HNSS in patients was handed.

Results: Thirty patients were included in the study. The mean symptom score values for HNSS at baseline, 3, 6, and 12 months' post-RT treatment were 17.8, 62.2, 64.4, and 20.8, respectively. Dryness and stickiness also increased over 3-6 months in follow-up but slightly relieved at 12 months, but it could not reach to baseline. In subgroup analysis, at baseline mean score of dryness of mouth in elderly patients (≥60 years) ( = 0.248), poor performance status (Eastern Cooperative Oncology Group 2) ( = 0.80) and patients with advanced stage (Stage III and IVA) ( = 0.185) was higher. Correlation of normal tissue complication probability for xerostomia with contralateral mean parotid gland showed insignificant linearity with shallow curve.

Conclusion: Patients remained symptomatic for xerostomia chiefly till 6 months' postirradiation, but it was slightly relieved in 12 months but could not reach the baseline. Dosimetric sparing ofcontralateral parotid resulted in decreased probability of developing xerostomia.

Citing Articles

Radical Resection of Malignant Tumors of Major Salivary Glands: Is This Possible?.

Cantu G Cancers (Basel). 2024; 16(4).

PMID: 38398078 PMC: 10886922. DOI: 10.3390/cancers16040687.

References

Ezzell G, Galvin J, Low D, Palta J, Rosen I, Sharpe M . Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys. 2003; 30(8):2089-115. DOI: 10.1118/1.1591194. View

Beetz I, Steenbakkers R, Chouvalova O, Leemans C, Doornaert P, van der Laan B . The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia. Acta Oncol. 2013; 53(5):597-604. DOI: 10.3109/0284186X.2013.831186. View

Beetz I, Schilstra C, van der Schaaf A, van den Heuvel E, Doornaert P, van Luijk P . NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother Oncol. 2012; 105(1):101-6. DOI: 10.1016/j.radonc.2012.03.004. View

Eisbruch A, Ten Haken R, Kim H, Marsh L, Ship J . Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999; 45(3):577-87. DOI: 10.1016/s0360-3016(99)00247-3. View

Beetz I, Schilstra C, van Luijk P, Christianen M, Doornaert P, Bijl H . External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiother Oncol. 2011; 105(1):94-100. DOI: 10.1016/j.radonc.2011.11.006. View

Beetz I, Schilstra C, Burlage F, Koken P, Doornaert P, Bijl H . Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. Radiother Oncol. 2011; 105(1):86-93. DOI: 10.1016/j.radonc.2011.05.010. View

Kouloulias V, Thalassinou S, Platoni K, Zygogianni A, Kouvaris J, Antypas C . The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: a systematic review with dosimetric and clinical parameters. Biomed Res Int. 2013; 2013:401261. PMC: 3818806. DOI: 10.1155/2013/401261. View

Gerds T, Cai T, Schumacher M . The performance of risk prediction models. Biom J. 2008; 50(4):457-79. DOI: 10.1002/bimj.200810443. View

Graff P, Lapeyre M, Desandes E, Ortholan C, Bensadoun R, Alfonsi M . Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 67(5):1309-17. DOI: 10.1016/j.ijrobp.2006.11.012. View

10.

Steyerberg E, Vickers A, Cook N, Gerds T, Gonen M, Obuchowski N . Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2009; 21(1):128-38. PMC: 3575184. DOI: 10.1097/EDE.0b013e3181c30fb2. View

11.

Hosmer D, Hosmer T, le Cessie S, Lemeshow S . A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997; 16(9):965-80. DOI: 10.1002/(sici)1097-0258(19970515)16:9<965::aid-sim509>3.0.co;2-o. View

12.

Vergouwe Y, Moons K, Steyerberg E . External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010; 172(8):971-80. PMC: 2984249. DOI: 10.1093/aje/kwq223. View

13.

Lee T, Chao P, Ting H, Chang L, Huang Y, Wu J . Using multivariate regression model with least absolute shrinkage and selection operator (LASSO) to predict the incidence of Xerostomia after intensity-modulated radiotherapy for head and neck cancer. PLoS One. 2014; 9(2):e89700. PMC: 3938504. DOI: 10.1371/journal.pone.0089700. View

14.

Pepe M, Janes H, Longton G, Leisenring W, Newcomb P . Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004; 159(9):882-90. DOI: 10.1093/aje/kwh101. View

15.

Cognetti D, Weber R, Lai S . Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113(7 Suppl):1911-32. PMC: 2751600. DOI: 10.1002/cncr.23654. View

16.

Lee S, Kim T, Park S, Pyo H, Shin K, Kim D . Evaluation of parotid gland function following intensity modulated radiation therapy for head and neck cancer. Cancer Res Treat. 2009; 38(2):84-91. PMC: 2741670. DOI: 10.4143/crt.2006.38.2.84. View